S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Options trading has suddenly become more reliable. (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The A.I. story nobody is telling you (Read ASAP) (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Options trading has suddenly become more reliable. (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The A.I. story nobody is telling you (Read ASAP) (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Options trading has suddenly become more reliable. (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The A.I. story nobody is telling you (Read ASAP) (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Options trading has suddenly become more reliable. (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The A.I. story nobody is telling you (Read ASAP) (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:ZEAL

Zealand Pharma A/S (ZEAL) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)
Free ZEAL Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$17.59
▼
$17.59
50-Day Range
$16.54
▼
$19.20
52-Week Range
$9.93
▼
$32.94
Volume
N/A
Average Volume
4,965 shs
Market Capitalization
$818.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
ZEAL stock logo

About Zealand Pharma A/S Stock (NASDAQ:ZEAL)

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

ZEAL Stock News Headlines

April 12, 2024 | ft.com
A ghost of Brexit past returns to haunt Labour
April 4, 2024 | morningstar.com
U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year
April 18, 2024 | Paradigm Press (Ad)
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
March 31, 2024 | msn.com
New Zealand cancer trial: CAR T-cell therapy for lymphoma, leukaemia and myeloma is saving lives
March 29, 2024 | msn.com
'Oppenheimer' director Christopher Nolan will receive a knighthood in the UK
March 28, 2024 | nz.finance.yahoo.com
Jessie J says she’s the opposite of a ‘beige mum’ as she shows off son’s playroom
March 28, 2024 | msn.com
New Zealand Education: International student enrolments top 59,000 for the first eight months of 2023
March 28, 2024 | msn.com
Ozempic maker Novo Nordisk gets more weight loss drug competition as a rival releases promising data
April 18, 2024 | Paradigm Press (Ad)
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
March 26, 2024 | globenewswire.com
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
March 26, 2024 | globenewswire.com
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
March 20, 2024 | globenewswire.com
Zealand Pharma's Annual General Meeting 2024
March 19, 2024 | globenewswire.com
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
March 17, 2024 | businessinsider.com
Weight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last year
March 15, 2024 | msn.com
What is amycretin? The new weight-loss pill that’s ‘twice as effective’ as Ozempic
March 14, 2024 | yahoo.com
Factbox-Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle
March 13, 2024 | globenewswire.com
New Employee Elected Directors to the Board of Zealand Pharma A/S
March 13, 2024 | msn.com
Who benefits from direct-to-consumer pharmaceutical advertising?
March 8, 2024 | globenewswire.com
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
March 5, 2024 | globenewswire.com
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
March 5, 2024 | globenewswire.com
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
March 1, 2024 | globenewswire.com
Zealand Pharma to Participate in TD Cowen's 44th Annual Health Care Conference
February 27, 2024 | finance.yahoo.com
Zealand Pharma A/S (ZEAL.CO)
February 27, 2024 | globenewswire.com
Zealand Pharma Announces Financial Results for the Full Year 2023
February 26, 2024 | cnbc.com
European markets close lower as investors await inflation data; Zealand Pharma up 35%
February 26, 2024 | uk.investing.com
Zealand Pharma stock soars 35% on strong trial results for its weight loss treatment
February 26, 2024 | msn.com
There might be a weight loss drug competitor to Ozempic — and the company's stock is soaring
See More Headlines
Receive ZEAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZEAL
CUSIP
N/A
CIK
1674988
Web
www.zealandpharma.com
Phone
(458) 877-3600
Fax
45-8877-3898
Employees
355
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($4.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-161,990,000.00
Net Margins
-565.44%
Pretax Margin
-364.34%
Return on Equity
-111.04%
Return on Assets
-56.54%

Debt

Debt-to-Equity Ratio
0.93
Current Ratio
4.79
Quick Ratio
4.78

Sales & Book Value

Annual Sales
$46.54 million
Price / Sales
17.59
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.38 per share
Price / Book
5.20

Miscellaneous

Outstanding Shares
46,538,000
Free Float
45,514,000
Market Cap
$818.60 million
Optionable
Not Optionable
Beta
1.45
Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Adam Sinding Steensberg M.D. (Age 48)
    Pres & CEO
    Comp: $680.16k
  • Mr. Ivan Mourits Moller (Age 50)
    Chief Operating Officer
  • Lani Pollworth Morvan
    Investor Relations & Communications Officer
  • Mr. Mads Kronborg
    Head of Investor Relations & Communication
  • Mr. Ravinder Chahil
    Sr. VP & Gen. Counsel
  • Ms. Christina Sonnenborg Bredal (Age 37)
    Sr. VP and Global Head of People & Organization
  • Ms. Hanne Heidenheim Bak (Age 69)
    Sr. Project Director, R&D Operations Mang. and Employee Representative Director
  • Dr. Jens Damsgaard Mikkelsen M.D.
    Head of Molecular Pharmacology
  • Dr. Danilo Verge
    Head of Global Medical Affairs
  • Dr. David M. Kendall M.D. (Age 60)
    Chief Medical Officer

Key Competitors

View All Competitors

ZEAL Stock Analysis - Frequently Asked Questions

Should I buy or sell Zealand Pharma A/S stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZEAL shares.
View ZEAL analyst ratings or view top-rated stocks.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (NASDAQ:ZEAL) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($4.61) EPS for the quarter, topping the consensus estimate of ($6.31) by $1.70. The company had revenue of $16.87 million for the quarter, compared to the consensus estimate of $12.21 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 111.04% and a negative net margin of 565.44%. During the same period last year, the company posted ($0.90) EPS.

What other stocks do shareholders of Zealand Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zealand Pharma A/S investors own include AbbVie (ABBV), Galapagos (GLPG), Verizon Communications (VZ), Dynavax Technologies (DVAX), EyePoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

When did Zealand Pharma A/S IPO?

Zealand Pharma A/S (ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

This page (NASDAQ:ZEAL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The Next Nvidia?
InvestorPlace
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
How Biden has already won 2024
Porter & Company